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http://www.wjso.com/content/12/1/111RESEARCH Open AccessLaparoscopic partial nephrectomy for multilocular
cystic renal cell carcinoma: a potential gold
standard treatment with excellent perioperative
outcomes
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Background: To report on the perioperative outcomes of laparoscopic partial nephrectomy (LPN) for multilocular
cystic renal cell carcinoma (MCRCC) and evaluate the feasibility of this minimally invasive technique as a potential
gold standard treatment for MCRCC.
Methods: We retrospectively reviewed the database of surgically pathological findings of patients who were
diagnosed with MCRCC at Peking University First Hospital and Chinese PLA General Hospital (Beijing, China)
between May 2009 and January 2013. A total of 42 patients with an average age of 48.3 years who were treated
with LPN were collected. The patients’ perioperative outcomes were reported and analyzed.
Results: All operations were performed successfully without massive hemorrhage or open conversion. None of
patients received lymph node dissection or metastasectomy. Two patients required postoperative transfusion with a
mean amount of 175 cc packed red blood cells. Only three patients experienced mild postoperative complications.
The mean operative time was 2.4 ± 1.2 hours, including the mean warm ischemia time (WIT) of 23.2 ± 5.7 minutes.
The mean estimated blood loss was 72.0 ± 49.6 ml. The mean retroperitoneal drainage was 4.4 ± 1.7 days. The mean
postoperative hospital stay was 6.1 ± 1.9 days. Pathologically, 40 (95.2%) of the tumors presented as stage
pT1abN0M0, while the remaining two (4.8%) presented as stage pT2aN0M0. No recurrences or new lesions
occurred in these patients at a mean follow-up time of 30.0 months.
Conclusions: Although the effective option of LPN is not yet the gold standard treatment for conventional renal
cell carcinoma, it should be strongly recommended as a potential gold standard treatment for MCRCC due to the
benign nature of MCRCC and the excellent perioperative outcomes provided by LPN.
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Multilocular cystic renal cell carcinoma (MCRCC) is a
rare renal tumor that was first recognized in 1982 [1],
and has a reported incidence of between 1% and 4% of
renal cell carcinomas (RCCs) [2,3]. In general, MCRCC
is associated with a low nuclear grade and stage and has
a favorable prognosis regardless of tumor size. The 2004
World Health Organization (WHO) classification of kid-
ney tumors also noted its diagnostic criteria and catego-
rized MCRCC as a separate entity with good prognosis
[4]. Due to the lack of clear radiological criteria and the
difficulty in distinguishing it from other types of renal
masses, surgical exploration is prompted for MCRCC.
In fact, the reasonable management of MCRCC is con-
troversial and thus needs clarification to avoid unneces-
sary overtreatment, such as radical nephrectomy (RN) in
simple cases. Partial nephrectomy (PN), also known as
nephron-sparing surgery (NSS), performed by an open or
a laparoscopic approach, might be proven feasible and ef-
ficient because MCRCC has been found not to be affected
adversely by large tumor size or advanced stage [5]. Re-
cently, growing experience with laparoscopic PN (LPN)
for conventional RCC has demonstrated its potential to
duplicate the techniques and outcomes of open partial
nephrectomy (OPN) [6]. In our opinion, LPN can simi-
larly be generalized to MCRCC, although handling the
cystic lesions is a more challenging procedure than in
RCC because of the greater potential for inadvertent cyst
puncture and tumor cell spillage [7]. Regrettably, there are
still no articles reporting on the perioperative outcomes of
LPN for the treatment of MCRCC. To the best of our
knowledge, we are the first to evaluate the feasibility of
this minimally invasive technique and recommend it as a
potential gold standard treatment for MCRCC.
Methods
Approval for this study was granted by the ethics commit-
tees of Peking University First Hospital and Chinese PLA
General Hospital (Beijing, China). Written informed con-
sent was obtained from all of the patients.
Patients
We retrospectively reviewed the database of patients who
were diagnosed with MCRCC between May 2009 and
January 2013 at Peking University First Hospital and Chinese
PLA General Hospital for surgically pathological findings.
Patients with bilateral lesions or who had previously
undergone renal surgery were excluded from the study.
Among them, LPN was performed on 42 patients (33 men
and 9 women) with a mean age of 48.3 years (range 32 to
72 years) by two experienced surgeons (QZ and GC).
The preoperative evaluations, including urine analysis,
serum creatinine (SCr) level, renal B-ultrasonography
and computed tomography (CT), were routinely appliedto all patients. Preoperatively, both surgeons independ-
ently evaluated the CT images, and consultation with
at least one radiologist was necessary to improve the
accuracy of preoperative diagnosis. After joint discus-
sions, all of the renal masses were confirmed as local-
ized MCRCC without lymph node involvement or
distant metastasis. A typical MCRCC is depicted in
Figure 1A,B,C,D. Patient demographics, intraoperative
variables and postoperative outcomes including follow-
up information were reported and analyzed. All of the
specimens were examined by at least two experienced
pathologists. If the two pathologists disagreed regard-
ing the pathological characteristics, a third specialist
was consulted. Clinical follow-up included physical
examination, SCr level, chest X-ray and abdominal CT
performed at 1 and 6 months and yearly thereafter; this
information was obtained from patient charts and refer-
ring physicians.
Surgical treatments
Only three-port, retroperitoneal LPN was performed in all
42 patients. Our surgical technique for treating MCRCC
followed essentially the same standard steps for handling
other renal tumors, as previously reported [8]. After the
construction of a retroperitoneal cavity, the paranephric
fat was dissected off Gerota’s fascia, which was sub-
sequently opened and incised away from the tumor
(Figure 2A) to facilitate excision and suturing. By dissec-
ting cautiously, the renal vessels were dissected free, and
the renal artery (RA) was clamped completely with laparo-
scopic bulldog clamps (Figure 2B), which was of utmost
importance in the treatment of MCRCC. With complete
occlusion, the tension of the affected kidney decreased im-
mediately, and the surgeon could obtain a specific tactile
sensation to avoid invading the cystic components when
dissecting the cystic tumor. After a transient occlusion,
the cystic lesion was sharply excised with cold scissors in
an almost bloodless field, and the suction device usually
accompanied the scissors to aid the separation from the
normal kidney (Figure 2C). Afterwards, hemostasis was
achieved by suturing any pelvicaliceal entry and using an
absorbable oxidized regenerated cellulose bolster. Follow-
ing renorrhaphy, the vascular clamp was removed, and
hemostasis was evaluated. Subsequently, the tumor was
retrieved with an endobag, and a suction drain was placed
in the retroperitoneal cavity. A representative image of
MCRCC is shown in Figure 2D.
Results
The detailed patient demographics and perioperative out-
come characteristics are listed in Table 1. All operations
were performed successfully without massive hemorrhage
or open conversion. None of the patients received lymph
node dissection or metastasectomy. Two patients required
Figure 2 Intraoperative photographs of LPN for MCRCC. (A) Laparoscopic photograph of the MCRCC with a clear margin from the normal
parenchyma. (B) The RA was exposed and clamped completely. (C) Laparoscopic photograph of a MCRCC separated from the normal renal
parenchyma with cold scissors and the suction device. (D) Gross image of resected MCRCC with multilocular cystic lesions. LPN, laparoscopic
partial nephrectomy; MCRCC, multilocular cystic renal cell carcinoma; RA, renal artery.
Figure 1 Preoperative CT scans of the abdomen revealed a typical MCRCC (white arrow). (A) Typical images of MCRCC localized to the
central location of the left kidney. (B) Typical images of MCRCC localized to the lower pole of the left kidney. (C) Typical images of MCRCC
localized to the lower pole of the left kidney. (D) Typical images of MCRCC localized to the upper pole of the left kidney. CT, computed
tomography; MCRCC, multilocular cystic renal cell carcinoma.
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Table 1 Patient demographics and perioperative outcome
characteristics
Variable Value
Number of patients 42







Tumor size (cm) 3.4 ± 1.6
Preoperative SCr level (mg/dl) 0.84 ± 0.14
Operative time (hours) 2.4 ± 1.2
WIT (minutes) 23.2 ± 5.7
Estimated blood loss (ml) 72.0 ± 49.6
Drainage days (days) 4.4 ± 1.7
Hospitalization (days) 6.5 ± 2.5






Fuhrman 1 35 (83.3%)
Fuhrman 2 7 (16.7%)
SCr, serum creatinine; WIT, warm ischemia time.
Xu et al. World Journal of Surgical Oncology 2014, 12:111 Page 4 of 6
http://www.wjso.com/content/12/1/111postoperative transfusion with a mean amount of 175 cc
packed red blood cells. Only three patients experienced
mild postoperative complications (two experienced perire-
nal fluid collection and one experienced excessive drain-
age), and they were treated successfully by infection
control and postponing withdrawal of the drainage tube.
The mean operative time was 2.4 ± 1.2 hours (range 1.0 to
4.2 hours), including the mean warm ischemia time
(WIT) of 23.2 ± 5.7 minutes (range 14 to 40 minutes). The
mean estimated blood loss was 72.0 ± 49.6 ml (range 5 to
200 ml). The mean retroperitoneal drainage was 4.4 ±
1.7 days (range 2 to 7 day). The mean postoperative hos-
pital stay was 6.1 ± 1.9 days (range 3 to 14 days). The SCr
levels were all within normal limits, with a preoperative
mean of 0.84 mg/dl (range 0.66 to 1.14 mg/dl) and a post-
operative mean of 1.01 mg/dl (range 0.62 to 1.48 mg/dl).
There was no significant difference (P = 0.207, >0.05) be-
tween pre- and postoperative SCr levels. Pathologically, all
42 tumors with a negative margin were confirmed to be
localized MCRCC (pN0M0) without any lymph node in-
volvement or distant metastasis detected as the previous
images had indicated. Among the tumors, 40 (95.2%)presented as stage pT1abN0M0, while the remaining two
(4.8%) presented as stage pT2aN0M0. Thirty-five patients
(83.3%) were classified into Fuhrman grade 1, and the
other seven cases (16.7%) were classified into Fuhrman
grade 2. The patients whose follow-up information was
available had no evidence of disease at a mean follow-up
time of 30.0 months. The cause-specific survival (CSS)
rates after undergoing LPN were 100% in the observation
periods.
Discussion
MCRCC, defined as an entirely cystic tumor with thin
septa containing clusters of Fuhrman grade 1 to 2 clear
cells that do not expand the septa [9], is an uncommon
histologic subtype (3%) of conventional RCC. Surgical
resection can indicate an excellent long-term prognosis
for MCRCC, and its biology appears to be more favor-
able with regards to important prognostic factors such
as metastatic presentation, Fuhrman grade, T stage and
tumor size [10].
Traditionally, in view of the possibility of tumor rupture
or spillage, the suitable treatment for MCRCC is RN.
However, at the initial diagnosis, MCRCCs tend to be
smaller tumors and have a lower T stage and nuclear
grade; therefore, these lesions may be more amenable to
PN. Due to accumulated experience with PN and im-
proved surgical techniques, increasing numbers of sur-
geons have chosen PN as the first therapy for MCRCC in
view of its benign nature. Gong et al. [11] suggested that
an NSS procedure should be considered when a complex
multicystic renal mass with enhanced density is observed.
In their opinion, rather like conventional RCC, MCRCC is
often located in the polar regions of the kidney, making an
NSS approach quite feasible. Moreover, You et al. [12] in-
dicated that 96% of patients with benign cysts or MCRCCs
>4 cm might be able to avoid RN and instead undergo
NSS, according to their recent findings. Our clinical data
from the present study have also added support to the
previous conclusions and, more importantly, have pro-
vided recommendations to apply minimally invasive LPN,
not OPN, as a potential gold standard treatment, although
open nephrectomy remains the gold standard treatment
for MCRCC [13].
For more than 4 years, we have been interested in the
minimally invasive management of MCRCC with LPN
rather than OPN. LPN has been demonstrated as a feas-
ible, efficient and safe technique in stage T1a and even
stage T1b conventional RCC, and it seems that LPN can
provide similar oncologic results to those of OPN [14].
In our series, all 42 MCRCC cases undergoing LPN
experienced successful operations and rehabilitation,
although some minor and not severe complications oc-
curred in the early learning curves. These patients not
only preserved more renal function with a normal
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without any recurrence or metastasis in the follow-up. In
fact, LPN has been an acceptable alternative to OPN for
the treatment of T1 renal masses [15], although LPN of
renal tumors >4 cm still cannot be considered a standard of
care [16], and OPN remains the standard of care according
to the European Association of Urology guidelines [17].
Some current studies of LPN largely reflect the experience
of skilled laparoscopic surgeons at centers of excellence.
Nevertheless, the rapid advances in laparoscopic equip-
ment, imaging modalities, renorrhaphy techniques and
hemostatic agents have narrowed the proficiency gap
to allow LPN to be performed routinely in community
settings. Therefore, in view of the fact that LPN has
been intensively applied in conventional RCC, mainly in
stage T1a conventional RCC, LPN can be considered as
an effective therapeutic strategy to treat at least stage
T1a MCRCC.
In addition to T1a MCRCC, we believe that larger tu-
mors classified as stage T1b or T2a can also be treated
by LPN. In this investigation, we successfully performed
LPN in six stage T1bN0M0 cases and in two stage
T2aN0M0 cases, in which performing LPN would seem
to be contraindicated. However, due to the benign char-
acteristics of these tumors, their size appears to be less
important when considering the detailed surgical ap-
proach. Some authors have also advocated NSS for renal
tumors >7 cm in the presence of a healthy contralateral
kidney [18]. Above all, the excellent perioperative out-
comes in this study combined with the other related lit-
erature have confirmed that LPN is an alternative to
open PN or RN for MCRCC. With the development of
our experience and skills, LPN has become the gold
standard treatment for MCRCC at our institutions.
Since 2011, a new treatment option of ‘zero-ischemia’
LPN has emerged under initially controlled hypotension
and later mainly by performing a ‘superselective microdis-
section’ [19,20]. Although some experts believe that ‘zero-
ischemia’ PN could be a safe and effective technique to
manage T1 renal tumors regardless of their complexity,
the extended operative time and longer learning curve for
this complex surgical procedure are obstacles for the ma-
jority of urologists to overcome for it to replace conven-
tional LPN as a gold standard treatment for MCRCC. For
evaluating the outcomes of PN, Hung et al. [21] have in-
troduced a ‘trifecta’ of criteria, which is the combination
of a negative cancer margin, minimal renal functional de-
crease and no urological complications. Based on these
criteria, no positive cancer margins or severe urological
complications were observed in our series. More impor-
tantly, excellent preservation of renal function was also
obtained, as shown by the postoperative SCr levels. Given
the superior perioperative outcomes with conventional
LPN for MCRCC, detractors of ‘zero-ischemia’ LPNcontinue to raise questions about the real benefits of this
procedure when treating MCRCC. In our analysis, only by
clamping the hilar vessels to provide a completely blood-
less field and a specific tactile sensation to avoid invading
the cystic components, can obtaining a negative surgical
margin and preserving substantial quantities of renal par-
enchyma be realized simultaneously; these outcomes can-
not yet be easily achieved with a ‘zero-ischemia’ technique.
Unlike in conventional RCC, it is especially important in
the treatment of MCRCC to avoid invading the cystic
components and creating tumor rupture or spillage; in
view of the benign characteristics of MCRCC, the ‘zero-is-
chemia’ technique is not so obvious for MCRCC. We be-
lieve that this technique could represent a significant step
toward safe and efficient LPN for MCRCC after undergo-
ing the learning curve, but not yet. Advanced ‘zero-ische-
mia’ skills are strongly required to achieve acceptable
results and there is still a long way to go.
Due to the limitations of our study, including its retro-
spective nature, the fact that it was performed at only
two institutions and the limited follow-up, it is still a
matter of controversy whether the potential gold stand-
ard treatment of LPN for MCRCC can turn into the ac-
tual gold standard treatment. Above all, longer and
larger prospective studies are still warranted to assess
the true advantages and make an accurate long-term as-
sessment of this surgical approach. We look forward to
the continuing development of other series to confirm
these encouraging results.
Conclusions
Our results, based on a large series of 42 cases, indicate
that LPN is a safe, efficient and minimally invasive therapy
for patients with MCRCC. Although the effective option
of LPN is not yet the gold standard treatment for conven-
tional RCC, it should be strongly recommended as a po-
tential gold standard treatment for MCRCC due to the
benign nature of MCRCC and the excellent perioperative
outcomes provided by LPN.
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